Skip to main content
NAGE logo

Niagen Bioscience, Inc.

NAGENASDAQHealthcareBiotechnology

$2.49Today:- (-)1Y −64.80%

As of Oct 16, 2026 close

Market cap
$212.86M
P/E (TTM)
13.31
Forward P/E
15.12
Dividend yield
-
52-week range
$2.51$7.95
Volume (live)
-
Avg. volume (3M)
505.20K

Niagen Bioscience (NAGE) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Niagen Bioscience had a P/E ratio of 29.26 (down from 47.50), return on equity of 28.3% (up from 22.9%), debt-to-equity of 0.04 (down from 0.06) and a current ratio of 4.86 (up from 3.57). A current ratio of 4.86 means current assets exceed current liabilities.

Niagen Bioscience Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio29.2647.50----
Forward P/E27.8150.28160.00160.00160.00-
P/S Ratio3.934.081.291.743.795.02
P/B Ratio6.658.813.784.378.0618.11
Price/Tangible Book7.188.883.854.488.2919.39
Price/FCF38.5033.9915.45---
Price/OCF37.6633.5415.13---
Enterprise Value Ratios
EV/Revenue3.463.781.011.623.354.79
EV/EBITDA29.6844.12----
EV/EBIT31.3148.76----
EV/FCF33.8731.5412.17---
Profitability & Returns
Return on Equity (ROE)28.35%22.94%-17.29%-54.77%-112.68%-108.08%
Return on Assets (ROA)10.23%7.84%-6.42%-20.81%-35.18%-31.57%
Return on Invested Capital (ROIC)144.16%169.60%-65.10%-176.99%-542.87%-776.15%
Return on Capital Employed (ROCE)16.50%15.40%-16.30%-51.50%-67.30%-90.70%
Leverage & Solvency Ratios
Debt/Equity0.040.060.120.150.150.10
Debt/EBITDA0.170.27----
Debt/FCF0.210.220.47---
Liquidity Ratios
Current Ratio4.863.572.402.612.781.96
Quick Ratio3.732.911.571.611.891.17
Efficiency Ratios
Asset Turnover1.481.621.531.291.401.51
Inventory Turnover3.123.212.252.072.052.07
Yield & Distribution Ratios
Earnings Yield3.42%2.11%-4.59%-13.19%-10.61%-6.70%
FCF Yield2.60%2.94%6.47%-12.30%-9.61%-3.60%
Buyback Yield-9.36%-4.19%-7.54%-3.79%-10.02%-7.03%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Niagen Bioscience Financial Ratios

What is Niagen Bioscience's P/E ratio?

Niagen Bioscience's P/E ratio was 29.26 for fiscal 2025 (period ended Dec 31, 2025). It was 47.50 a year earlier.

What is Niagen Bioscience's return on equity?

Niagen Bioscience's return on equity (ROE) was 28.3% for fiscal 2025 (period ended Dec 31, 2025). It was 22.9% a year earlier.

What is Niagen Bioscience's debt-to-equity ratio?

Niagen Bioscience's debt-to-equity ratio was 0.04 for fiscal 2025 (period ended Dec 31, 2025). It was 0.06 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition